Profile cover photo
Profile photo
BioTime
130 followers -
Developing stem cell-based therapies and products in the area of regenerative medicine
Developing stem cell-based therapies and products in the area of regenerative medicine

130 followers
About
Posts

Post has attachment
BioTime’s Renevia® Achieves Primary Endpoint in European Pivotal Trial

• Data Reinforce Renevia’s Potential in Multi-Billion Dollar Facial Aesthetics Market

• BioTime on Track to File for Renevia CE Mark by End of 2017

• Conference Call Today with Lead Investigator at 4:30 p.m. ET
Add a comment...

Post has attachment
Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias' AST-OPC1

Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on at least one side

$AST
$BTX

Add a comment...

Post has attachment
BioTime Presents Retinal Restoration Data at ARVO

> Demonstrates Ability to Grow Full-Thickness, 3-D Retinal Tissue

> Tissue is Highly Similar to Natural Human Tissue

$BTX

http://bit.ly/2q5XT2p
Add a comment...

Post has attachment
BioTime to Present Additional Data at Upcoming ARVO

> Retinal tissue regeneration presentation added

> OpRegen® presentation scheduled for May 8

$BTX
#RegenMed

http://bit.ly/2psFltC
Add a comment...

Post has attachment
BioTime Forms New Subsidiary AgeX Therapeutics, Inc. to Develop its Programs Focused on Human Aging

Objective is to quickly establish leadership in the emerging biotechnology field of Aging through pluripotency and iTR™ assets

BioTime continues execution of corporate simplification strategy while remaining focused on Ophthalmology, Aesthetics and Therapeutics Delivery

Add a comment...

Post has attachment
BioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6

Will Present on the Promise of Pluripotent Cells in Advanced Therapeutics and the Company’s Plans to Develop Applications in Human Aging

$BTX
#regenmed

http://bit.ly/2nAdfHG
Add a comment...

Post has attachment


Data From BioTime’s OpRegen® Trial in Dry-AMD to be Presented at ARVO on May 8, in Baltimore, Maryland
#ARVO2017
$BTX
Add a comment...

Post has attachment

BioTime Expands OpRegen® Clinical Trial in Dry-AMD With Opening of First US Sites
$BTX
http://bit.ly/2mC96nF
Add a comment...

Post has attachment
Read GEN's coverage of the opening of our new cGMP cell therapy manufacturing center in Israel.

Add a comment...
Wait while more posts are being loaded